{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:13:48Z","timestamp":1791843228080,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"19-20","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s10354-008-0594-z","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T12:11:44Z","timestamp":1226319104000},"page":"553-557","source":"Crossref","is-referenced-by-count":33,"title":["Cholestasis and metabolic bone disease \u2013 a clinical review","Cholestase und metabolische Knochenerkrankung \u2013 eine \u00dcbersicht"],"prefix":"10.1007","volume":"158","author":[{"given":"Rudolf W.","family":"Gasser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"594_CR1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0016-5085(95)90033-0","volume":"108","author":"JE Hay","year":"1995","unstructured":"Hay JE. Bone disease in cholestatic liver disease. Gastroenterology, 108: 276\u2013283, 1995","journal-title":"Gastroenterology"},{"key":"594_CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/jhep.2001.20533","volume":"33","author":"S Rouillard","year":"2001","unstructured":"Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology, 33: 301\u2013307, 2001","journal-title":"Hepatology"},{"key":"594_CR3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/CRIAI:28:2:147","volume":"28","author":"T Pusl","year":"2005","unstructured":"Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases pathogenesis and therapy. Clin Rev Allerg Immunol, 28: 147\u2013157, 2005","journal-title":"Clin Rev Allerg Immunol"},{"key":"594_CR4","doi-asserted-by":"crossref","first-page":"239A","DOI":"10.1053\/jhep.2000.9546","volume":"32","author":"J Hay","year":"2000","unstructured":"Hay J, Guichelaar M, Egan K, Therneau T. Bone mineral density in the first decade after liver transplantation. Hepatology, 32: 239A (abstract), 2000","journal-title":"Hepatology"},{"key":"594_CR5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/jhep.2002.36357","volume":"36","author":"MMJ Guichelaar","year":"2002","unstructured":"Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology, 36: 895\u2013903, 2002","journal-title":"Hepatology"},{"key":"594_CR6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.0106-9543.2002.01566.x","volume":"22","author":"Z Ackerman","year":"2002","unstructured":"Ackerman Z, Weinreb M, Amir G, Pollak RD. Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease. Liver, 22: 166\u2013172, 2002","journal-title":"Liver"},{"key":"594_CR7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2003.11.032","volume":"40","author":"M Weinreb","year":"2004","unstructured":"Weinreb M, Pollak RD, Ackerman Z. Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis. J Hepatol, 40: 385\u2013390, 2004","journal-title":"J Hepatol"},{"key":"594_CR8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00042737-200503000-00009","volume":"17","author":"A Pares","year":"2005","unstructured":"Pares A, Guanabens N, Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol, 17: 311\u2013315, 2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"594_CR9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(03)00143-0","volume":"38","author":"JE Hay","year":"2003","unstructured":"Hay JE. Osteoporosis in liver diseases and after liver transplantation. J Hepatol, 38: 856\u2013865, 2003","journal-title":"J Hepatol"},{"key":"594_CR10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0016-5085(82)80291-6","volume":"83","author":"DS Matloff","year":"1982","unstructured":"Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology, 83: 97\u2013102, 1982","journal-title":"Gastroenterology"},{"key":"594_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0016-5085(82)80292-8","volume":"83","author":"HF Herlong","year":"1982","unstructured":"Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology, 83: 103\u2013108, 1982","journal-title":"Gastroenterology"},{"key":"594_CR12","first-page":"2059","volume":"92","author":"KV Kowdley","year":"1997","unstructured":"Kowdley KV, Emond MJ, Sadoeski JA, Kaplan MM. Plasma vitamin K1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol, 92: 2059\u20132061, 1997","journal-title":"Am J Gastroenterol"},{"key":"594_CR13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0168-8278(01)00133-7","volume":"35","author":"S Nishiguchi","year":"2001","unstructured":"Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T, Kubo S. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol, 35: 543\u2013545, 2001","journal-title":"J Hepatol"},{"key":"594_CR14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2265.2007.02765.x","volume":"66","author":"AT de Albuquerque Taveira","year":"2007","unstructured":"de Albuquerque Taveira AT, Fernandes MIM, Galvao LC, Sawamura R, de Mello Vieira E, Albuquerque de Paula FJ. Impairment of bone mass development in children with chronic cholestatic liver disease. Clinical Endocrinology, 66: 518\u2013523, 2007","journal-title":"Clinical Endocrinology"},{"key":"594_CR15","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1172\/JCI117959","volume":"95","author":"CH Janes","year":"1995","unstructured":"Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of Hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest, 95: 2581\u20132586, 1995","journal-title":"J Clin Invest"},{"key":"594_CR16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","volume":"35","author":"K Menon","year":"2001","unstructured":"Menon K, Angulo P, Weston S, Dickson E, Lindor K. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol, 35: 316\u2013323, 2001","journal-title":"J Hepatol"},{"key":"594_CR17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jocd.2005.10.001","volume":"9","author":"DL Smith","year":"2006","unstructured":"Smith DL, Shire NJ, Watts NB, Schmitter T, Szabo G, Zucker SD. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. J Clin Densitom, 9: 105\u2013113, 2006","journal-title":"J Clin Densitom"},{"key":"594_CR18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0168-8278(02)00435-X","volume":"38","author":"F Szalay","year":"2003","unstructured":"Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol, 38: 395\u2013400, 2003","journal-title":"J Hepatol"},{"key":"594_CR19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1478-3231.2007.01448.x","volume":"27","author":"A Monegal","year":"2007","unstructured":"Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodes J, Guanabens N. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. Liver Int, 27: 492\u2013497, 2007","journal-title":"Liver Int"},{"key":"594_CR20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2005.05.034","volume":"43","author":"AR Moschen","year":"2005","unstructured":"Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, M\u00fchllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL\/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol, 43: 973\u2013983, 2005","journal-title":"J Hepatol"},{"key":"594_CR21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1530\/eje.0.1320444","volume":"132","author":"H Bell","year":"1995","unstructured":"Bell H, Raknerud N, Falch JA, Haug E. Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol, 132: 444\u2013449, 1995","journal-title":"Eur J Endocrinol"},{"key":"594_CR22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00042737-199703000-00012","volume":"9","author":"S Pignata","year":"1997","unstructured":"Pignata S, Daniele B, Galati MG, Esposito G, Vallone P, Fiore F, Ricchi P, Pergola M. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 9: 283\u2013286, 1997","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"594_CR23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/alcalc\/agl004","volume":"41","author":"E Garcia-Valdecasas-Campelo","year":"2006","unstructured":"Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santolaria-Fernandez F, De la Vega-Prieto MJ, Milena-Abril A, Sanchez-Perez MJ, Martinez-Riera A, Gomez-Rodriguez MDLA. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcoholism, 41: 261\u2013266, 2006","journal-title":"Alcohol Alcoholism"},{"issue":"2","key":"594_CR24","first-page":"CD003778","volume":"18","author":"M Prince","year":"2005","unstructured":"Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst Rev Apr, 18(2): CD003778, 2005","journal-title":"Cochrane Database Syst Rev Apr"},{"key":"594_CR25","doi-asserted-by":"crossref","unstructured":"Chen W, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev, (3): CD004036, 2004","DOI":"10.1002\/14651858.CD004036.pub2"},{"key":"594_CR26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cld.2005.07.003","volume":"9","author":"JE Hay","year":"2005","unstructured":"Hay JE, Guichelaar MMJ. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis, 9: 747\u2013766, 2005","journal-title":"Clin Liver Dis"},{"key":"594_CR27","first-page":"1","volume":"843","author":"Report of WHO Study Group","year":"1994","unstructured":"Report of WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, World Health Organ Tech Rep Ser, 843: 1\u2013129, 1994","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"Suppl I","key":"594_CR28","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/gut.50.suppl_1.i1","volume":"50","author":"JD Collier","year":"2002","unstructured":"Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut, 50(Suppl I): i1\u2013i9, 2002","journal-title":"Gut"},{"key":"594_CR29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2006.06.007","volume":"45","author":"A Pares","year":"2006","unstructured":"Pares A, Guanabens N. Treatment of bone disorders in liver disease. J Hepatol, 45: 445\u2013453, 2006","journal-title":"J Hepatol"},{"key":"594_CR30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11938-006-0002-y","volume":"9","author":"NM Maalouf","year":"2006","unstructured":"Maalouf NM, Sakhaee K. Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients. Curr Treatment Options Gastroenterol, 9: 456\u2013463, 2006","journal-title":"Curr Treatment Options Gastroenterol"},{"key":"594_CR31","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","volume":"98","author":"N Guanabens","year":"2003","unstructured":"Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L, Monegal A, Martinez de Osaba MJ, Roca M, Peris P, Rodes J. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol, 98: 2268\u20132274, 2003","journal-title":"Am J Gastroenterol"},{"key":"594_CR32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","volume":"42","author":"CO Zein","year":"2005","unstructured":"Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomised placebo-controlled trial. Hepatology, 42: 762\u2013771, 2005","journal-title":"Hepatology"},{"key":"594_CR33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1478-3231.2005.01026.x","volume":"25","author":"C Levy","year":"2005","unstructured":"Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic woman with primary biliary cirrhosis: results of a pilot study. Liver Int, 25: 117\u2013121, 2005","journal-title":"Liver Int"},{"key":"594_CR34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2036.2004.01890.x","volume":"19","author":"SP Pereira","year":"2004","unstructured":"Pereira SP, O'Donohue J, Moniz C, Phillips MG, Abraha H, Buxton-Thomas M, Williams R. Transdermal hormonal replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther, 19: 563\u2013570, 2004","journal-title":"Aliment Pharmacol Ther"},{"key":"594_CR35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2796.2004.01342.x","volume":"256","author":"S Ormarsdottir","year":"2004","unstructured":"Ormarsdottir S, Mallmin H, Naessen T, Petren-Mallmin M, Broome U, Hultcranz R, L\u00f6\u00f6f L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med, 256: 63\u201369, 2004","journal-title":"J Intern Med"},{"key":"594_CR36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","volume":"51","author":"RH Boone","year":"2006","unstructured":"Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin. Dig Dis Sci, 51: 1103\u20131112, 2006","journal-title":"Dig Dis Sci"},{"key":"594_CR37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288: 321\u2013333, 2002","journal-title":"JAMA"},{"key":"594_CR38","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/lt.20874","volume":"12","author":"MMJ Guichelaar","year":"2006","unstructured":"Guichelaar MMJ, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl, 12: 1390\u20131402, 2006","journal-title":"Liver Transpl"},{"key":"594_CR39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/lt.20466","volume":"11","author":"G Millonig","year":"2005","unstructured":"Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Tanspl, 11: 960\u2013966, 2005","journal-title":"Liver Tanspl"},{"key":"594_CR40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/0003-4819-144-4-200602210-00005","volume":"144","author":"BAL Crawford","year":"2006","unstructured":"Crawford BAL, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med, 144: 239\u2013248, 2006","journal-title":"Ann Intern Med"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-008-0594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-008-0594-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-008-0594-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T10:46:25Z","timestamp":1709376385000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-008-0594-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":40,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s10354-008-0594-z","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}